- Date2025-11-18
Publication of Review Result of the 7th Pharmaceutical Reimbursement Evaluation Committee of 2025
□ The Health Insurance Review and Assessment Service (HIRA, President: Kang Jung-Gu) announces the results deliberated by the 7th Drug Benefit Evaluation Committee in 2025.
○ Deliberation Results on the Appropriateness of Reimbursement for the Requested Drugs
|
Product |
Manufacturer |
Indications |
Deliberation Results |
|
Citrulline Oral Disintegrating Tablets 5 mg (Taltirelin Hydrate) |
HLB Pharmaceutical Co., Ltd. |
Improvement of ataxia caused by spinocerebellar degeneration |
Reimbursement deemed appropriate if accepted at or below the evaluated price |
|
Bilberry Capsule 200, 400, 600, 1,200 μg (Odevixibat 1.5 Hydrate) |
Ipsen Korea Co., Ltd |
Treatment of pruritus in patients with progressive familial intrahepatic cholestasis (PFIC) |
Reimbursement deemed appropriate |
|
※ In accordance with Article 11-2 of the “Regulations on Standards for National Health Insurance Benefits,” the President of the Health Insurance Review and Assessment Service (HIRA) evaluates the appropriateness of drug coverage through deliberation by the Drug Benefit Evaluation Committee. The detailed coverage scope of the drug may differ from its indications, and the final evaluation results may change in the event of changes to standard items, modifications, or withdrawal (cancellation) of the approved specifications of the requested drug, or other relevant circumstances. |
